Lipitor Case Proves Strength Of Molecular Patents

Law360, New York (December 20, 2005, 12:00 AM EST) -- During Pfizer’s Inc.’s drawn out patent bout over blockbuster drug Lipitor, its long-time counsel Connolly Bove Lodge & Hutz LLP had a significant task that promised to affect an entire industry regardless of the outcome.

India-based generic drug maker Ranbaxy Laboratories took the unusual step of seeking to invalidate Lipitor’s molecular compound patent, the very heart of a drug’s intellectual property.

The daring attack, an attempt to break into Lipitor’s wild financial success as the world’s top-selling drug, has so far failed. That may bring a...
To view the full article, register now.